- **Q: What is the current price trend for Bayer stock?
**
Yanuki
ARTICLE DETAIL
Bayer Stock: Still Under Pressure? | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | Bayer Stock: Still Under Pressure? | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026
Finance / Stocks
Bayer Stock: Still Under Pressure?
Bayer AG's stock has shown minor gains recently, but the broader picture reveals significant pressure. This article recaps the latest performance data, financial results, and analyst outlooks compiled by Yanuki using the latest trends and d...
Key Insights
- **Recent Performance:** The stock price hovered around €20.76 - €20.93 in mid-April 2025, showing a slight daily increase (+0.22% to +0.44%) but remains significantly down over 30 days (>12%) and the past year (>20%).
- **Technical Indicators:** The stock is trading well below its 52-week high of €30.48 (over 30% lower) and has breached the 50-day and 200-day moving averages, signaling a bearish trend. The 52-week low was €18.38.
- **Financials:** Bayer reported a loss per share of €0.34 in Q4 2024 (compared to a profit of €1.36 in Q4 2023) on slightly lower revenue (€11.73 billion, down 1.12% year-over-year).
- **Dividend:** A minimal dividend of €0.111 per share is expected for the current fiscal year, similar to the previous year (€0.110).
- **Analyst Outlook:** Despite recent poor performance, analysts forecast an average EPS of €4.44 for the full year 2025. However, concerns remain, with AlphaValue/Baader Europe lowering EPS estimates citing a potential capital increase.
- **Why this matters:** The stock's decline, coupled with a quarterly loss and low dividend, reflects ongoing financial challenges and requires careful monitoring by investors.
In-Depth Analysis
Bayer's stock presents a mixed picture for investors. While occasional daily upticks occur, the dominant trend has been negative, with substantial losses over monthly and yearly periods. The share price remains significantly depressed compared to its 52-week high and struggles below key technical benchmarks like the 50-day and 200-day moving averages.
The company's Q4 2024 results highlighted these difficulties, swinging to a net loss from a profit the previous year, alongside a slight revenue dip. The dividend forecast remains minimal, offering little solace to income investors.
Looking ahead, analysts project a potential recovery with an average EPS forecast of €4.44 for 2025. However, achieving this requires overcoming current headwinds. Recent analyst actions reflect caution; Jefferies & Company Inc. maintains a 'Hold' rating, and AlphaValue/Baader Europe has adjusted EPS expectations downward due to the possibility of a capital raise, which could dilute existing shares. Investors should closely watch the upcoming Q1 2025 results, expected around May 13, 2025, for clearer signs of the company's trajectory.
FAQ
- **Q: What are Bayer's recent financial results?
**
- **Q: What do analysts expect for Bayer in 2025?
**
Takeaways
- Bayer's stock is currently facing significant downward pressure despite minor short-term fluctuations.
- Recent financial performance, including a Q4 loss and minimal dividend, underscores the challenges.
- While analysts see potential for earnings recovery in 2025, investors should be aware of risks, including potential share dilution from a capital increase.
- Keep an eye on the Q1 2025 earnings report (expected May 13, 2025) for further insight.
Discussion
Do you think Bayer can meet the optimistic analyst expectations for 2025 despite the current pressures? Let us know!
*Share this article with others who need to stay ahead of this trend!*
Sources
Source 1: Bayer Aktie: Weiter unter Druck? (Börse Express)
Source 2: Bayer Aktie News: Bayer gibt am Nachmittag nach (finanzen.ch)
Source 3: AlphaValue/Baader Europe senkt die EPS-Schätzungen von Bayer (MarketScreener)
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.